Corey Maas
Plastic and Reconstructive Surgery · San Francisco, CANPI 1851469282
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $220,053 of the $286,076 with a category attached, or 76.9%. AbbVie accounts for 87.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $71,754 and has fallen 66.9% since, to $23,757 in 2025. Among plastic and reconstructive surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 297 payments — averaging $963.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$250K
- Merz North America, Inc.$34K
- Galderma Laboratories, L.p.$931
- Endo Pharmaceuticals Inc.$820
- Revance Therapeutics, Inc.$321
- Solta Medical, A Division Of Bausch Health US, LLC$54
- plus $142 from 4 others
Across 63 payments — averaging $19,460 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1M
- Merz North America, Inc.$190K
- Endo Pharmaceuticals Inc.$13K
What the payments were for
- Consulting fees$220,05377%
- Speaking & faculty fees$31,66411%
- Travel & lodging$23,4648%
- Food & beverage$10,8954%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 210 | $249,830 |
| Merz North America, Inc. | 48 | $33,978 |
| Galderma Laboratories, L.p. | 18 | $931 |
| Endo Pharmaceuticals Inc. | 11 | $820 |
| Revance Therapeutics, Inc. | 4 | $321 |
| Solta Medical, A Division Of Bausch Health US, LLC | 2 | $54 |
| Polarityte, Inc. | 1 | $50 |
| Motiva USA, LLC | 1 | $40 |
| Pacira Pharmaceuticals Incorporated | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$101,346
- BOTOX COSMETIC$54,488
- XEOMIN$26,149
- KYBELLA$12,000
- NATRELLE SALINE-FILLED BREAST IMPLANTS$1,817
- DAXXIFY$250
How this compares
$286,076 in reported general payments places this provider in the 95th percentile of 349 plastic and reconstructive surgery providers in California.
See all plastic and reconstructive surgery providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spironolactone | 33 | $309 |
| Minoxidil | 21 | $251 |
Paid to pharmacies, not to this prescriber.
Other plastic and reconstructive surgery in San Francisco
- Charles LeeSan Francisco$200K
- David SieberSan Francisco$195K
- Gregory BunckeSan Francisco$105K
- Thomas SatterwhiteSan Francisco$11K
- Mark SuskiThousand Oaks$294K
- Arian MowlaviLaguna Beach$250K
- David KulberLos Angeles$194K
- Matthew NykielUpland$181K
- Subhas GuptaLoma Linda$178K
- Jeffrey HammoudehLos Angeles$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.